MBB Public Markets I LLC Makes New $313,000 Investment in Edwards Lifesciences Corporation $EW

Key Points

• MBB Public Markets I LLC has initiated a new position in Edwards Lifesciences Corporation, acquiring 4,322 shares valued at approximately $313,000 during the first quarter.
• Edwards Lifesciences reported earnings of $0.67 per share for the latest quarter, surpassing estimates, with revenues reaching $1.53 billion, up 11.9% year-over-year.
• Several analysts have upgraded their price targets for Edwards Lifesciences, with estimates ranging from $80.00 to $95.00, indicating a generally positive outlook for the stock.

MBB Public Markets I LLC acquired a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,322 shares of the medical research company's stock, valued at approximately $313,000.

A number of other large investors also recently modified their holdings of the company. Vega Investment Solutions bought a new position in Edwards Lifesciences in the 4th quarter valued at $27,000. Quantbot Technologies LP bought a new position in Edwards Lifesciences in the 1st quarter valued at $26,000. SouthState Corp bought a new position in Edwards Lifesciences in the 1st quarter valued at $27,000. Rossby Financial LCC bought a new position in Edwards Lifesciences in the 1st quarter valued at $29,000. Finally, Costello Asset Management INC bought a new position in Edwards Lifesciences in the 1st quarter valued at $29,000. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider owned 206,900 shares in the company, valued at $15,565,087. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,014 shares of company stock worth $1,698,844 in the last 90 days. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Down 0.7%

Edwards Lifesciences stock traded down $0.51 during mid-day trading on Friday, hitting $77.50. The company's stock had a trading volume of 6,301,589 shares, compared to its average volume of 3,595,766. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock has a market cap of $45.50 billion, a price-to-earnings ratio of 11.15, a price-to-earnings-growth ratio of 3.76 and a beta of 1.07. The business has a 50 day moving average price of $78.92 and a 200-day moving average price of $75.42. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the previous year, the company earned $0.70 earnings per share. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on EW. Citigroup reissued a "buy" rating and issued a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a report on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. William Blair raised shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Finally, Evercore ISI lifted their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus target price of $86.26.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.